Hematology

Nurses play a key role in treating patients with myeloma.

A majority of adult patients with β-thalassemia who require regular red blood cell (RBC) transfusions experienced clinically meaningful and durable transfusion burden reduction associated with luspatercept (Reblozyl) in the phase III BELIEVE trial.

CAR T-cell therapy is an emerging targeted therapy that has large potential for patients whose disease is relapsed or refractory.

The combination of lenalidomide (Revlimid) and obinutuzumab (Gazyva) elicited a 100% overall response rate (ORR) in patients with relapsed indolent non-Hodgkin lymphoma (NHL) that was refractory to rituximab (Rituxan), according to findings of a single-arm, phase I/II trial presented at the 2019 ASH Annual Meeting.

Steroid use while cytokine release syndrome (CRS) and neurologic toxicities are at grade 1, instead of waiting until grade 3, reduces the rate of CAR T-cell treatment–related CRS and neurologic events.

The US Food and Drug Administration (FDA) has granted breakthrough therapy designation to abatacept (Orencia) to prevent moderate or severe acute graft-versus-host disease (GvHD) in patients who underwent a hematopoietic stem cell transplant and are not related to their donors, according to Bristol-Myers Squibb, the manufacturer of the drug.

JAK inhibitors have been the standard of care for patients with myelofibrosis, but now patients need novel agents to help.

New approvals in the treatment of patients with myeloma has led to the question of what sequencing of drugs will work best for patients.

The FDA has approved acalabrutinib for the treatment of adult patients with CLL or SLL.

The Food and Drug Administration granted accelerated approval to zanubrutinib for the treatment of relapsed and refractory mantle cell lymphoma.

Elderly patients with AML have long faced limited options for their treatment, but that is no longer the case. However, challenges still remain in the treatment of this patient population.

Precision medicine is sweeping across the cancer care spectrum, and now, experts have their sights set on applying it in MCL.

Any patient with cancer needs a caregiver through the treatment journey, but it's even more vital for patients with cancer undergoing the stem cell transplant process.

The FDA has granted an RMAT designation for an investigational CAR-T cell therapy used to treat patients with multiple myeloma.

Frahad Ravandi-Kashani, MD, had the chance to discuss the role of MRD in treating patients with hairy cell leukemia.

New research and techniques indicate an easier path forward for identifying hairy cell leukemia.

MRD can prove useful in the treatment of patients with hairy cell leukemia who relapsed.

For patients with hairy cell leukemia, it's complications after treatment that can be life-threatening.

At the 2019 Hairy Cell Leukemia Foundation Annual Conference new findings showed promise in the safety of vemurafenib to treat patients with hairy cell leukemia.

Chemotherapy is often associated with devastating toxicities, but moxetumomab pasudotox appears to be manageable based on the findings from a new trial.

A label update from the FDA has approved a sBLA for romiplostim to include data demonstrating sustained platelet responses in adults with ITP.

A study of patients with chronic lymphocytic leukemia looked into the role of treatment and disease itself in cognitive impairment.

After being diagnosed with essential thrombocythemia, former NHL referee Kerry Fraser did his best to maintain a positive attitude – and he says his oncology nurses played a huge role in that.

When patients with MCL develop resistance to chemotherapy and targeted therapies, experts believe CAR T-cell therapy can step in.

Earlier today, the FDA approved daratumumab, in combination with other treatments, to treat patients with multiple myeloma that are eligible for autologous stem cell transplant.

CAR T-cell therapy is changing the landscape of cancer care, but challenges for certain cancer types still remain.

Patients – and their caregivers too – should be key players in their multiple myeloma treatment planning.

Pediatric patients with ALL can expect therapies to help target their disease after they relapse, but experts are looking to combat the disease in the frontline before that.

Treating patients with multiple myeloma can be difficult, but in the past several months there have been a large number of promising updates to potential new combinations of treatment.

The Centers for Medicare and Medicaid Services (CMS) announced that it will cover chimeric antigen receptor (CAR) T-cell therapy for Medicare beneficiaries.